SUB-INDUSTRY Cell/Gene Therapy
Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™.
Genenta was seeking to raise new capital to progress in the clinical studies in order to:
- advance the ongoing GBM clinical program
- conduct an Italian clinical Phase 2 synthetic controlled study of Temferon
- fund Temferon manufacturing activities for the Phase 2 trial
IL SUPPORTO DELL’ADVISOR
Growth Capital has advised Genenta’s management team.
Connecting outstanding entrepreneurs and visionary investors